These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 33506914

  • 1. Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis.
    Shuai ZQ, Zhang CX, Shuai ZW, Ge SL.
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):250-262. PubMed ID: 33506914
    [Abstract] [Full Text] [Related]

  • 2. Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis.
    Barra L, Yang G, Pagnoux C, Canadian Vasculitis Network (CanVasc).
    Autoimmun Rev; 2018 Jul; 17(7):683-693. PubMed ID: 29729444
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: A systematic review of randomized controlled trials.
    Singh A, Danda D, Hussain S, Najmi AK, Mathew A, Goel R, Lakhan SE, Tajudheen B, Antony B.
    Mod Rheumatol; 2021 Jan; 31(1):197-204. PubMed ID: 32000551
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review.
    Li H, Shuai Z.
    Heart Vessels; 2022 May; 37(5):884-894. PubMed ID: 34750666
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis.
    Misra DP, Rathore U, Patro P, Agarwal V, Sharma A.
    Clin Rheumatol; 2021 Nov; 40(11):4391-4416. PubMed ID: 33932173
    [Abstract] [Full Text] [Related]

  • 8. Corticosteroid monotherapy for the management of Takayasu arteritis-a systematic review and meta-analysis.
    Misra DP, Rathore U, Patro P, Agarwal V, Sharma A.
    Rheumatol Int; 2021 Oct; 41(10):1729-1742. PubMed ID: 34302232
    [Abstract] [Full Text] [Related]

  • 9. Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis.
    Pan L, Du J, Liu J, Liao H, Liu X, Guo X, Liang J, Han H, Yang L, Zhou Y.
    Clin Rheumatol; 2020 Aug; 39(8):2369-2378. PubMed ID: 32144625
    [Abstract] [Full Text] [Related]

  • 10. Pentraxin 3 is more accurate than C-reactive protein for Takayasu arteritis activity assessment: A systematic review and meta-analysis.
    Wen X, Hou R, Xu K, Han Y, Hu J, Zhang Y, Su Y, Gao J, Zhang G, Zhang L.
    PLoS One; 2021 Aug; 16(2):e0245612. PubMed ID: 33529185
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
    Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N.
    Ann Rheum Dis; 2018 Mar; 77(3):348-354. PubMed ID: 29191819
    [Abstract] [Full Text] [Related]

  • 12. Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab.
    Alibaz-Oner F, Kaymaz-Tahra S, Bayındır Ö, Yazici A, Ince B, Kalkan K, Kanıtez NA, Kocaer SB, Yasar Bilge NS, Omma A, Durak E, Ilgın C, Akar S, Kaşifoğlu T, Önen F, Emmungil H, İnanç M, Cefle A, Aksu K, Keser G, Direskeneli H.
    Semin Arthritis Rheum; 2021 Dec; 51(6):1224-1229. PubMed ID: 34706312
    [Abstract] [Full Text] [Related]

  • 13. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.
    Osman M, Pagnoux C, Dryden DM, Storie D, Yacyshyn E.
    PLoS One; 2014 Dec; 9(12):e115026. PubMed ID: 25517966
    [Abstract] [Full Text] [Related]

  • 14. Biological treatments in giant cell arteritis & Takayasu arteritis.
    Samson M, Espígol-Frigolé G, Terrades-García N, Prieto-González S, Corbera-Bellalta M, Alba-Rovira R, Hernández-Rodríguez J, Audia S, Bonnotte B, Cid MC.
    Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of tocilizumab for intractable Takayasu arteritis and 18F-fluorodeoxyglucose-positron emission tomography for detecting inflammation under tocilizumab treatment.
    Isobe M, Maejima Y, Saji M, Tateishi U.
    J Cardiol; 2021 May; 77(5):539-544. PubMed ID: 33451862
    [Abstract] [Full Text] [Related]

  • 16. Development of severe colitis in Takayasu arteritis treated with tocilizumab.
    Ishii K, Shirai T, Kakuta Y, Machiyama T, Sato H, Ishii T, Harigae H, Fujii H.
    Clin Rheumatol; 2022 Jun; 41(6):1911-1918. PubMed ID: 35188603
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of biological agents in patients with giant cell arteritis: A meta-analysis of randomized trials.
    Song GG, Lee YH.
    Int J Clin Pharmacol Ther; 2020 Sep; 58(9):504-510. PubMed ID: 32567545
    [Abstract] [Full Text] [Related]

  • 18. The comparative safety of biological treatment in patients with axial spondylarthritis: a meta-analysis of randomized controlled trials with placebo.
    Sun WT, He YH, Dong MM, Zhang YN, Peng KX, Zhang YM, Lin YD, Yang C, Peng PX.
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):9824-9836. PubMed ID: 33090385
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.